(NASDAQ: IMUX) Immunic's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.8%.
Immunic's earnings in 2025 is -$103,047,000.On average, 10 Wall Street analysts forecast IMUX's earnings for 2025 to be -$89,744,433, with the lowest IMUX earnings forecast at -$107,269,917, and the highest IMUX earnings forecast at -$66,938,449. On average, 9 Wall Street analysts forecast IMUX's earnings for 2026 to be -$56,257,165, with the lowest IMUX earnings forecast at -$119,057,820, and the highest IMUX earnings forecast at -$6,314,948.
In 2027, IMUX is forecast to generate -$65,759,659 in earnings, with the lowest earnings forecast at -$96,660,804 and the highest earnings forecast at -$44,204,636.